Ho Jin Kim

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Achim Berthele, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 846 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim et al. · The Lancet · 2019 · 717 citations

Medicine, Neurology, Pharmacotherapy +4

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

Su‐Hyun Kim, So‐Young Huh, Sun Ju Lee et al. · JAMA Neurology · 2013 · 322 citations

Life Sciences, Neurology, Pharmacotherapy +15

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

Su‐Hyun Kim, In Hye Jeong, Jae‐Won Hyun et al. · JAMA Neurology · 2015 · 210 citations

Life Sciences, Immunology, Pharmacotherapy +11

Natalizumab effects on immune cell responses in multiple sclerosis

Masaaki Niino, Caroline Bodner, Marie‐Lune Simard et al. · Annals of Neurology · 2006 · 210 citations

Life Sciences, Immunology, Pharmacology +15